{"product_id":"bispecific-antibodies-for-blood-cancers-what-a-major-review-of-36-studies-found-about-benefits-and-safety","title":"Bispecific Antibodies for Blood Cancers: What a Major Review of 36 Studies Found About Benefits and Safety","description":"\u003cp\u003eA systematic review of 36 clinical studies covering 19 different bispecific antibodies (BsAbs) found that these engineered immune drugs have established, meaningful activity in three blood cancers: B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell non-Hodgkin lymphoma (NHL), and multiple myeloma (MM). Blinatumomab remains the most studied agent in relapsed or refractory BCP-ALL, with complete response (CR) rates of 31.11% to 64.00% and measurable residual disease (MRD) clearance rates of 70.45% to 88.00%. In contrast, bispecific antibodies in acute myeloid leukemia (AML), Hodgkin lymphoma (HL), and T-cell lymphoma (TCL) remain early-phase with limited efficacy and no regulatory approvals to date. Safety is the main trade-off: cytokine release syndrome (CRS) occurred in 1.59% to 82.61% of patients across studies, and neurologic events exceeded 50% in several Blinatumomab trials, while cytopenias (low blood cell counts) and infections remain major challenges in multiple myeloma.\u003c\/p\u003e\n\n\u003ch1\u003eBispecific Antibodies for Blood Cancers: What a Major Review of 36 Studies Found About Benefits and Safety\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Researchers Conducted the Review\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#selection\"\u003eHow Many Studies Were Included\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#characteristics\"\u003eWhat the Included Studies Looked Like\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#landscape\"\u003eWhich Bispecific Antibodies Are Approved Today\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#leukemia\"\u003eKey Findings: Leukemia\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#lymphoma\"\u003eKey Findings: Lymphoma\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#myeloma\"\u003eKey Findings: Multiple Myeloma\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety-overall\"\u003eSafety: The Overall Side Effect Picture\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#crs\"\u003eSafety: Cytokine Release Syndrome\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#neuro\"\u003eSafety: Neurotoxicity, Cytopenias, and Infections\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Review Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and What to Ask Your Care Team\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eA review of 36 studies found bispecific antibodies have established activity in B-cell precursor ALL, B-cell non-Hodgkin lymphoma, and multiple myeloma, but not yet in AML, Hodgkin lymphoma, or T-cell lymphoma.\u003c\/li\u003e\n\u003cli\u003eIn relapsed or refractory B-cell precursor ALL, Blinatumomab produced complete response rates of 31.11% to 64.00% and MRD clearance rates of 70.45% to 88.00% across the studies reviewed.\u003c\/li\u003e\n\u003cli\u003eCytokine release syndrome occurred in 1.59% to 82.61% of patients; most cases were grade 1 to 2, typically appearing within 1 to 2 days and resolving within 2 to 3 days.\u003c\/li\u003e\n\u003cli\u003eNeurologic events occurred in more than 50% of patients in several Blinatumomab studies, making neurologic monitoring a central part of care for anyone receiving these drugs.\u003c\/li\u003e\n\u003cli\u003eBispecific antibodies are off-the-shelf therapies that do not require the personalized manufacturing of CAR-T therapy, which can allow faster treatment initiation and broader patient access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eHematologic neoplasms (cancers that start in the blood, bone marrow, or lymphatic system) are a growing global health problem. Doctors classify them by where they begin: leukemias arise in the blood, lymphomas develop in the lymph nodes, and myelomas originate in the bone marrow.\u003c\/p\u003e\n\n\u003cp\u003eAmong leukemias, \u003cstrong\u003eacute myeloid leukemia (AML)\u003c\/strong\u003e is the most common acute leukemia in adults. AML is marked by significant genetic and clonal heterogeneity — meaning the cancer cells are not all identical, and this variety is one reason the disease resists treatment.\u003c\/p\u003e\n\n\u003cp\u003eLymphomas are split into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). NHL represents about \u003cstrong\u003e90% of all lymphoma cases\u003c\/strong\u003e and arises from lymphocytes (a type of white blood cell) at different stages of development. \u003cstrong\u003eMultiple myeloma (MM)\u003c\/strong\u003e accounts for roughly \u003cstrong\u003e10% of all hematologic neoplasms\u003c\/strong\u003e. It remains incurable and typically follows an asymptomatic precursor state, meaning patients often have abnormal blood proteins for years before symptoms appear.\u003c\/p\u003e\n\n\u003cp\u003eThe burden of these diseases has climbed over the last three decades. Both new cases (incidence) and deaths (mortality) have risen, especially in older populations. Patients with blood cancers also face higher risks of treatment-related complications and higher death rates compared with patients who have solid tumors, such as lung or breast cancer. The median age at diagnosis is \u003cstrong\u003e70.8 years\u003c\/strong\u003e, and overall \u003cstrong\u003e5-year relative survival is 69.2%\u003c\/strong\u003e — a figure that reflects real progress in treatment.\u003c\/p\u003e\n\n\u003cp\u003eThat progress includes chemotherapy, monoclonal antibodies (mAbs, laboratory-made immune proteins that target one specific marker), and chimeric antigen receptor T (CAR-T) cell therapy (a treatment where a patient's own T cells are genetically reprogrammed to attack cancer). Even so, many patients still experience treatment failure because of relapse, resistance, or simply a shortage of good options.\u003c\/p\u003e\n\n\u003cp\u003eBispecific antibodies (BsAbs) are a newer answer to that problem. These engineered molecules can bind two different targets (epitopes) at the same time. That dual targeting increases specificity and helps overcome drug resistance.\u003c\/p\u003e\n\n\u003cp\u003eWhy does dual targeting matter? Traditional monoclonal antibodies and CAR-T therapies often fail when tumor cells lose the antigen (the surface marker) the treatment is aiming at. Two well-known examples are \u003cstrong\u003eCD19 loss\u003c\/strong\u003e in B-cell cancers and \u003cstrong\u003eB-cell maturation antigen (BCMA) loss\u003c\/strong\u003e in multiple myeloma. When the target disappears, the treatment stops working. Bispecific antibodies get around this by engaging multiple antigens or multiple immune effectors at once — for instance, simultaneously grabbing a tumor marker such as CD19, CD20, or BCMA while also grabbing an immune trigger such as CD3 on T cells or CD16A on natural killer cells. This ensures the tumor cell keeps being recognized and destroyed.\u003c\/p\u003e\n\n\u003cp\u003eThere is a practical advantage, too. CAR-T therapy requires personalized manufacturing and long processing times, which can take weeks. Bispecific antibodies are off-the-shelf therapies, meaning they are pre-made and ready to give. That allows rapid treatment initiation and broader patient access.\u003c\/p\u003e\n\n\u003cp\u003eAmong bispecific antibodies, \u003cstrong\u003ebispecific T-cell engagers (BiTEs)\u003c\/strong\u003e — molecules that physically link T cells to cancer cells — have shown the most promise in blood cancers. This has led to several recent FDA approvals, including Blinatumomab for Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (Ph-negative R\/R BCP-ALL), Mosunetuzumab for relapsed or refractory follicular lymphoma (R\/R FL), and Epcoritamab for diffuse large B-cell lymphoma (DLBCL).\u003c\/p\u003e\n\n\u003cp\u003eDespite this rapid expansion, no comprehensive systematic review had evaluated the safety and efficacy of bispecific antibodies across \u003cem\u003eall\u003c\/em\u003e hematologic neoplasms. That is the gap this review set out to fill.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Researchers Conducted the Review\u003c\/h2\u003e\n\n\u003cp\u003eThe authors followed the PRISMA 2020 guidelines, an internationally accepted standard for reporting systematic reviews. They registered their protocol in advance with PROSPERO, the international prospective register of systematic reviews (registration number CRD42023467556). Registering a protocol in advance means the researchers committed to their methods before seeing the results, which reduces the chance of bias.\u003c\/p\u003e\n\n\u003cp\u003eThe team searched four major bibliographic databases: PubMed, Scopus, Web of Science, and EMBASE. They also searched ClinicalTrials.gov, the U.S. registry of clinical trials. Search terms and eligibility criteria were built around the PICO strategy (Population, Intervention, Comparator, Outcomes):\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePopulation:\u003c\/strong\u003e Adults with hematologic neoplasms — leukemia, lymphoma, and multiple myeloma.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntervention:\u003c\/strong\u003e Bispecific antibodies that engage CD3 and those that do not, with no formal comparator required.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEfficacy outcomes:\u003c\/strong\u003e Measurable residual disease (MRD), very good partial response (VGPR), overall response rate (ORR), complete response (CR), stringent complete response (sCR), progression-free survival (PFS), and overall survival (OS).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSafety outcomes:\u003c\/strong\u003e Serious adverse events (SAEs), grade ≥3 adverse events, treatment discontinuation, treatment-related mortality, cytokine release syndrome (CRS), neurotoxicity\/immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias (low blood cell counts), infections, and hypogammaglobulinemia (low levels of protective antibodies).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe search covered database inception through \u003cstrong\u003e20 June 2026\u003c\/strong\u003e. Importantly, the team applied no language or publication date filters, so they captured the full span of bispecific antibody research in blood cancers. They also performed backward and forward citation tracking — checking the reference lists of included studies and looking for later papers that cited them — and ran an updated search one month before submitting the manuscript.\u003c\/p\u003e\n\n\u003cp\u003eTwo researchers screened all retrieved titles and abstracts independently, then reviewed full texts independently to confirm eligibility. Any disagreements were settled through discussion or by consulting a third reviewer. Data were extracted using a standardized, pre-piloted form in Microsoft Excel.\u003c\/p\u003e\n\n\u003cp\u003eFor quality assessment, the team used two validated tools. The \u003cstrong\u003eROBINS-I\u003c\/strong\u003e tool (Risk Of Bias In Non-randomized Studies – of Interventions) was applied to non-randomized phase I–II studies. The \u003cstrong\u003eCochrane RoB2\u003c\/strong\u003e tool was applied to phase III randomized trials. For single-arm dose-escalation studies, the researchers adapted ROBINS-I V2 to focus on bias domains relevant to safety and dose-finding signals, with emphasis on confounding, participant selection, missing data, and selective reporting. Judgments were made separately for each key outcome.\u003c\/p\u003e\n\n\u003cp\u003eA planned meta-analysis (a statistical technique that pools results from multiple studies into one combined estimate) turned out to be unfeasible. The studies were too heterogeneous — too different in design, patient populations, and dosing — and the available data were too limited. The authors therefore summarized the results qualitatively, describing patterns rather than calculating a single pooled number.\u003c\/p\u003e\n\n\u003cp\u003eTwo final notes on method: patients and the public were not involved in designing, conducting, reporting, or disseminating this research. And because the study did not involve human participants or animals directly, research ethics approval was not applicable.\u003c\/p\u003e\n\n\u003ch2 id=\"selection\"\u003eHow Many Studies Were Included\u003c\/h2\u003e\n\n\u003cp\u003eThe search process was extensive. The researchers identified \u003cstrong\u003e10,847 references\u003c\/strong\u003e in total, broken down as follows:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ePubMed: 2,733 references\u003c\/li\u003e\n  \u003cli\u003eEmbase: 1,888 references\u003c\/li\u003e\n  \u003cli\u003eScopus: 2,365 references\u003c\/li\u003e\n  \u003cli\u003eWeb of Science: 3,861 references\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAfter removing 6,209 duplicate references, \u003cstrong\u003e4,638 publications\u003c\/strong\u003e went through title and abstract screening. Of these, 3,130 records were excluded, and 6 references could not be retrieved in full text. That left 1,502 publications evaluated by full text. A further 1,466 publications were excluded for various reasons. In the end, \u003cstrong\u003e36 articles\u003c\/strong\u003e were included in the qualitative and quantitative data synthesis.\u003c\/p\u003e\n\n\u003ch2 id=\"characteristics\"\u003eWhat the Included Studies Looked Like\u003c\/h2\u003e\n\n\u003cp\u003eAll 36 trials were published between \u003cstrong\u003e2014 and 2026\u003c\/strong\u003e. They covered three predominant tumor types: leukemia, lymphoma, and multiple myeloma — with lymphoma being the most prevalent category.\u003c\/p\u003e\n\n\u003cp\u003eThe median age of patients in the studies ranged from \u003cstrong\u003e32 to 70 years\u003c\/strong\u003e, and most participants were male. Just one publication involved newly diagnosed patients (a study by Katz and colleagues published in 2022 in DLBCL). Every other study focused on people with relapsed or refractory disease — meaning the cancer had come back or had stopped responding to prior treatment.\u003c\/p\u003e\n\n\u003cp\u003eThese were heavily pretreated patients. The median number of prior lines of therapy ranged from \u003cstrong\u003eone to seven\u003c\/strong\u003e. The 19 bispecific antibodies in the review were given either by intravenous (IV) infusion into a vein or by subcutaneous injection under the skin.\u003c\/p\u003e\n\n\u003ch2 id=\"landscape\"\u003eWhich Bispecific Antibodies Are Approved Today\u003c\/h2\u003e\n\n\u003cp\u003eThe review paints a clear picture of where the field stands by disease type.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIn leukemia, CD3–CD19 bispecific antibodies — particularly intravenous Blinatumomab — are the most clinically mature.\u003c\/strong\u003e The drug has completed four phase II trials and one phase III trial, and it holds regulatory approvals for relapsed or refractory B-cell precursor ALL from 2014 and 2024. A subcutaneous formulation of Blinatumomab was recently evaluated in a phase I\/II trial. Meanwhile, CD3–CD123 antibodies in AML — APVO436, Flotetuzumab, and JNJ-63709178 — remain in early-phase development, and none has received regulatory approval. Two more agents, the CD3–CD33 antibody AMG 330 and the CD3–HLA-A2–WT1 antibody RO7283420, were studied in phase I trials. AMG 330 was terminated, while RO7283420 completed phase I evaluation in 2023.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIn lymphoma, CD3–CD20 antibodies have become the dominant class\u003c\/strong\u003e, building on earlier experience with CD3–CD19 agents. Multiple candidates have completed phase I and II trials, and several phase III studies are ongoing. Beyond CD3–CD20 and CD3–CD19 agents, a CD20–CD37 bispecific antibody was evaluated in a phase Ia study. CD16A–CD30 antibodies were first tested in Hodgkin lymphoma, with limited clinical development for a period, until more recent studies extended their use to peripheral T-cell lymphoma (PTCL).\u003c\/p\u003e\n\n\u003cp\u003eTwo lymphoma approvals stand out. Epcoritamab received FDA approval for relapsed or refractory follicular lymphoma in combination with lenalidomide and rituximab in 2025. Mosunetuzumab expanded from its previously approved intravenous formulation to include a subcutaneous formulation the same year.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIn multiple myeloma, the story has moved fastest.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2022:\u003c\/strong\u003e Teclistamab became the first BCMA-targeting bispecific antibody to receive FDA approval.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2023:\u003c\/strong\u003e The GPRC5D-targeting antibody Talquetamab and the BCMA-targeting antibody Elranatamab were approved.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJuly 2025:\u003c\/strong\u003e The BCMA-targeting antibody Linvoseltamab received accelerated FDA approval.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMarch 2026:\u003c\/strong\u003e Teclistamab received approval in combination with daratumumab hyaluronidase-fihj.\u003c\/li\u003e\n  \u003cli\u003eTeclistamab was also the only agent with an active (not recruiting) phase III trial.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"leukemia\"\u003eKey Findings: Leukemia\u003c\/h2\u003e\n\n\u003cp\u003eThirty-four studies were included in the efficacy analysis. The authors excluded two studies — one by Boyiadzis and colleagues and one by Plesner and colleagues — because those publications reported no efficacy data.\u003c\/p\u003e\n\n\u003cp\u003eIn relapsed or refractory B-cell precursor ALL, Blinatumomab showed substantial clinical activity:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComplete response (CR) rates:\u003c\/strong\u003e 31.11% to 64.00% (roughly 3 in 10 to 6 in 10 patients)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRD response rates:\u003c\/strong\u003e 70.45% to 88.00% (about 7 in 10 to nearly 9 in 10 patients)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHSCT bridging rates:\u003c\/strong\u003e 20.00% to 67.27% (hematopoietic stem cell transplant — the share of patients who went on to transplant)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian progression-free survival (PFS):\u003c\/strong\u003e 5.00 to 18.90 months\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian overall survival (OS):\u003c\/strong\u003e 6.10 to 36.50 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMRD response rates were consistently high across studies, including in the trial evaluating the subcutaneous formulation. MRD negativity is important because it means no detectable cancer cells remain on sensitive testing.\u003c\/p\u003e\n\n\u003cp\u003eAcross studies, higher HSCT bridging rates were generally reported alongside longer PFS and OS. The authors caution, however, that this observation should be interpreted carefully. Study populations and designs differed, so it is not possible to conclude that transplant itself caused the longer survival.\u003c\/p\u003e\n\n\u003cp\u003eData in Philadelphia chromosome-positive (Ph+) ALL remain more limited. In the Ph+ ALL study included, Blinatumomab achieved an MRD negativity rate of \u003cstrong\u003e87.50%\u003c\/strong\u003e, an HSCT bridging rate of \u003cstrong\u003e20.00%\u003c\/strong\u003e, a median PFS of \u003cstrong\u003e6.8 months\u003c\/strong\u003e, and a median OS of \u003cstrong\u003e9.0 months\u003c\/strong\u003e. These results must be read in the context of distinct disease biology, prior therapies, and the growing use of tyrosine kinase inhibitors (TKIs) in combination strategies.\u003c\/p\u003e\n\n\u003cp\u003eIn AML, results were far more modest. Bispecific antibodies targeting CD3–CD123, CD3–CD33, and CD3–HLA-A2–WT1 showed only preliminary antileukemic activity:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHSCT rates:\u003c\/strong\u003e 2.38% to 25.00%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCR rates:\u003c\/strong\u003e 5.00% to 11.36%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian OS:\u003c\/strong\u003e 3.2 to 5.93 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"lymphoma\"\u003eKey Findings: Lymphoma\u003c\/h2\u003e\n\n\u003cp\u003eIn B-cell non-Hodgkin lymphoma, CD3–CD20 bispecific antibodies showed substantial antitumor activity, though response rates varied by lymphoma subtype.\u003c\/p\u003e\n\n\u003cp\u003eIn relapsed or refractory DLBCL (diffuse large B-cell lymphoma) or large B-cell lymphoma, the antibodies produced clinically meaningful activity:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall response rate (ORR):\u003c\/strong\u003e 51.97% to 68.31% (about 5 in 10 to 7 in 10 patients)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComplete response (CR) rate:\u003c\/strong\u003e 31.50% to 58.47%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian duration of response (DoR):\u003c\/strong\u003e 10.20 to 12.00 months\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian PFS:\u003c\/strong\u003e 4.40 to 13.80 months\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian OS:\u003c\/strong\u003e 9.20 to 25.50 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eResults in relapsed or refractory follicular lymphoma (FL) were even stronger:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall response rate:\u003c\/strong\u003e 80.00% to 95.06% (8 in 10 to more than 9 in 10 patients)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComplete response rate:\u003c\/strong\u003e 60.00% to 82.72%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian duration of response:\u003c\/strong\u003e 18.00 to 22.80 months\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian PFS:\u003c\/strong\u003e 17.90 months, reported in one study\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOverall, the authors observed considerable heterogeneity — wide variation — in response rates, response depth, and how long responses lasted. In contrast, therapeutic activity in AML, Hodgkin lymphoma, and peripheral T-cell lymphoma remained limited.\u003c\/p\u003e\n\n\u003ch2 id=\"myeloma\"\u003eKey Findings: Multiple Myeloma\u003c\/h2\u003e\n\n\u003cp\u003eIn multiple myeloma, CD3–BCMA and CD3–GPRC5D bispecific antibodies demonstrated substantial clinical activity across a broad range of measures.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall response rate:\u003c\/strong\u003e 30.95% to 84.46% (about 3 in 10 to 8 in 10 patients)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVery good partial response (VGPR) rates:\u003c\/strong\u003e 4.76% to 32.41%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStringent complete response (sCR) rates:\u003c\/strong\u003e 3.85% to 53.72%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRD response rates (among studies reporting MRD):\u003c\/strong\u003e 7.69% to 92.86%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian duration of response:\u003c\/strong\u003e 5.50 to 29.40 months\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian PFS:\u003c\/strong\u003e 2.83 to 11.30 months\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian OS:\u003c\/strong\u003e 16.00 to 31.40 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDeep responses — including VGPR and stringent complete response — were a notable feature of this drug class in myeloma. As with lymphoma, however, the range across studies was wide, reflecting differences in patient populations, prior treatments, and antibody targets.\u003c\/p\u003e\n\n\u003ch2 id=\"safety-overall\"\u003eSafety: The Overall Side Effect Picture\u003c\/h2\u003e\n\n\u003cp\u003eSafety remains a major challenge in bispecific antibody therapy across blood cancers. The toxicity profile varied according to the antibody construct, the target antigen, the disease type, and the dosing strategy.\u003c\/p\u003e\n\n\u003cp\u003eAcross studies, the numbers were striking:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSerious adverse events (SAEs):\u003c\/strong\u003e 12.17% to 91.30% of patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade ≥3 adverse events (severe side effects):\u003c\/strong\u003e 27.42% to 95.65% of patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDespite these high toxicity rates, \u003cstrong\u003etreatment discontinuation generally remained below 20%\u003c\/strong\u003e across studies, and treatment-related mortality was uncommon. In other words, side effects were frequent and sometimes severe, but most patients and their doctors chose to continue treatment.\u003c\/p\u003e\n\n\u003cp\u003eThere were two notable exceptions. A phase I study of a CD3–HLA-A2–WT1 bispecific antibody in AML reported a treatment discontinuation rate of \u003cstrong\u003e34.21%\u003c\/strong\u003e. And a phase III study of Glofitamab in DLBCL reported a discontinuation rate of \u003cstrong\u003e57.92%\u003c\/strong\u003e — the highest in the review. Overall, the authors conclude that severe adverse events were frequent, while treatment discontinuation and treatment-related mortality remained low.\u003c\/p\u003e\n\n\u003ch2 id=\"crs\"\u003eSafety: Cytokine Release Syndrome\u003c\/h2\u003e\n\n\u003cp\u003eCytokine release syndrome (CRS) was the most common immune-mediated toxicity of CD3-engaging bispecific antibodies. CRS happens when immune cells release a flood of inflammatory signaling molecules (cytokines) after treatment, causing fever, chills, low blood pressure, and sometimes breathing difficulty.\u003c\/p\u003e\n\n\u003cp\u003eAcross studies, CRS incidence ranged from \u003cstrong\u003e1.59% to 82.61%\u003c\/strong\u003e — an enormous range that reflects differences in antibody targets, dosing, and how aggressively CRS was monitored and reported.\u003c\/p\u003e\n\n\u003cp\u003eThe reassuring news is in the details. Most CRS events were \u003cstrong\u003egrade 1–2\u003c\/strong\u003e, meaning mild to moderate. They typically developed within \u003cstrong\u003e1 to 2 days\u003c\/strong\u003e after treatment initiation and resolved within \u003cstrong\u003e2 to 3 days\u003c\/strong\u003e. This timing pattern matters for patients and care teams, because it means the highest-risk window is short and predictable.\u003c\/p\u003e\n\n\u003cp\u003eTeclistamab (CD3–BCMA) and Talquetamab (CD3–GPRC5D) were associated with frequent CRS, and neurotoxicity was also reported with these agents. In multiple myeloma specifically, hematologic toxicity (blood-related side effects) and infections remain major challenges.\u003c\/p\u003e\n\n\u003ch2 id=\"neuro\"\u003eSafety: Neurotoxicity, Cytopenias, and Infections\u003c\/h2\u003e\n\n\u003cp\u003eNeurotoxicity — damage or dysfunction in the nervous system — was the other dominant toxicity of CD3-engaging agents. In several Blinatumomab studies, \u003cstrong\u003eneurologic events occurred in more than 50% of patients\u003c\/strong\u003e. This makes neurologic monitoring a central part of care for anyone receiving these drugs.\u003c\/p\u003e\n\n\u003cp\u003eBeyond CRS, neurotoxicity, cytopenias, and infections were identified as key safety considerations across the field. Cytopenias refer to low counts of blood cells — red cells, white cells, or platelets — and they can lead to fatigue, infection risk, and bleeding problems. The review also tracked hypogammaglobulinemia (low levels of protective antibodies), which can increase susceptibility to infections.\u003c\/p\u003e\n\n\u003cp\u003eThe authors note that the toxicity profile was not uniform. It varied according to the specific bispecific antibody construct, the target antigen, the underlying disease, and the dosing schedule used.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe practical takeaway is that bispecific antibodies now have an established place in three blood cancers — B-cell precursor ALL, B-cell non-Hodgkin lymphoma, and multiple myeloma — but not yet in AML, Hodgkin lymphoma, or T-cell lymphoma.\u003c\/p\u003e\n\n\u003cp\u003eFor patients with relapsed or refractory B-cell precursor ALL, Blinatumomab offers a well-documented path to deep responses and, for many, a bridge to stem cell transplant. For patients with follicular lymphoma, response rates above 80% are notable. For patients with multiple myeloma who have been through several prior lines of therapy, BCMA- and GPRC5D-targeting antibodies can produce deep responses, including MRD negativity, in a substantial proportion of patients.\u003c\/p\u003e\n\n\u003cp\u003eFor patients with AML, Hodgkin lymphoma, or T-cell lymphoma, the picture is different. These antibodies remain under investigation, and the review found limited efficacy and no approvals to date.\u003c\/p\u003e\n\n\u003cp\u003eSafety management is not a side issue — it is central to treatment. The predictable timing of CRS (usually within 1 to 2 days) and the fact that most cases are grade 1–2 and resolve within 2 to 3 days are useful facts for patients preparing for treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Review Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eSeveral limitations are worth understanding.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo pooled analysis was possible.\u003c\/strong\u003e The authors planned a meta-analysis but could not perform one because the studies were too heterogeneous and the data too limited. That means no single combined estimate of benefit or risk exists across the whole field.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWide ranges instead of precise numbers.\u003c\/strong\u003e When results vary as much as they do here (for example, CRS rates from 1.59% to 82.61%), it is difficult to predict an individual patient's experience from the published literature.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMost studies enrolled relapsed or refractory patients.\u003c\/strong\u003e Only one included study involved newly diagnosed patients, so the findings largely describe patients whose cancer had already returned or stopped responding.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHeavily pretreated populations.\u003c\/strong\u003e Patients had received a median of one to seven prior lines of therapy, which affects both response rates and tolerability.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComparison across studies is imperfect.\u003c\/strong\u003e The authors specifically caution that the link between higher transplant bridging rates and longer survival should be read carefully, because study populations and designs differed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors also note that data in Philadelphia chromosome-positive ALL remain more limited and should be interpreted in the context of distinct disease biology, prior therapy, and the increasing use of tyrosine kinase inhibitors in combination strategies.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and What to Ask Your Care Team\u003c\/h2\u003e\n\n\u003cp\u003eThe review's authors conclude that further studies should optimize treatment strategies and evaluate emerging targets, including non-CD3-engaging bispecific antibodies. Based on the findings, here are practical steps and questions for patients and families:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk whether a bispecific antibody is approved for your specific cancer type and setting.\u003c\/strong\u003e Approvals currently exist in B-cell precursor ALL, certain B-cell lymphomas, and multiple myeloma — not in AML, Hodgkin lymphoma, or T-cell lymphoma.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about your target antigen.\u003c\/strong\u003e Whether your cancer expresses CD19, CD20, BCMA, or GPRC5D determines which agents are relevant to you.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about CRS monitoring and mitigation.\u003c\/strong\u003e CRS typically appears within 1 to 2 days of treatment and resolves within 2 to 3 days. Ask what monitoring, step-up dosing, or premedication your center uses.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about neurologic monitoring.\u003c\/strong\u003e Neurologic events occurred in more than half of patients in several Blinatumomab studies. Report any confusion, tremor, difficulty speaking, or weakness immediately.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about infection prevention.\u003c\/strong\u003e Cytopenias and infections remain major challenges, particularly in multiple myeloma. Discuss vaccination, immunoglobulin levels, and infection precautions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about clinical trials.\u003c\/strong\u003e If you have AML, Hodgkin lymphoma, or T-cell lymphoma, a trial may be the most relevant route to these therapies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about the treatment-free advantages.\u003c\/strong\u003e Bispecific antibodies are off-the-shelf and do not require the personalized manufacturing that CAR-T therapy does, which can allow faster treatment initiation.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eAsk your care team how these findings apply to your individual situation. Response rates and side effect profiles vary widely by disease, prior treatment, and antibody target — and this review describes group-level patterns, not individual predictions.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhich blood cancers can bispecific antibodies treat today?\u003c\/h3\u003e\n\u003cp\u003eA review of 36 studies found established activity in three blood cancers: B-cell precursor acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma, and multiple myeloma. In acute myeloid leukemia, Hodgkin lymphoma, and T-cell lymphoma, these drugs remain early-phase with limited efficacy and no regulatory approvals to date. Ask your care team whether an approved bispecific antibody exists for your specific cancer type and setting.\u003c\/p\u003e\n\u003ch3\u003eWhat response rates did Blinatumomab achieve in relapsed or refractory B-cell precursor ALL?\u003c\/h3\u003e\n\u003cp\u003eAcross the studies reviewed, Blinatumomab produced complete response rates of 31.11% to 64.00% and measurable residual disease clearance rates of 70.45% to 88.00% in relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Median progression-free survival ranged from 5.00 to 18.90 months, and median overall survival from 6.10 to 36.50 months. These are group-level ranges, not individual predictions.\u003c\/p\u003e\n\u003ch3\u003eWhat is cytokine release syndrome and when does it happen?\u003c\/h3\u003e\n\u003cp\u003eCytokine release syndrome happens when immune cells release a flood of inflammatory signaling molecules after treatment, causing fever, chills, low blood pressure, and sometimes breathing difficulty. Across the studies reviewed, it occurred in 1.59% to 82.61% of patients. Most cases were grade 1 to 2, typically appearing within 1 to 2 days of treatment and resolving within 2 to 3 days. Ask your center about monitoring and premedication.\u003c\/p\u003e\n\u003ch3\u003eHow common are neurologic side effects with these drugs?\u003c\/h3\u003e\n\u003cp\u003eNeurologic events occurred in more than 50% of patients in several Blinatumomab studies, making neurologic monitoring a central part of care for anyone receiving these drugs. Report confusion, tremor, difficulty speaking, or weakness immediately. Neurotoxicity was also reported with Teclistamab and Talquetamab. The overall toxicity profile varied by antibody construct, target antigen, disease type, and dosing schedule, so ask your care team what to expect in your situation.\u003c\/p\u003e\n\u003ch3\u003eDo bispecific antibodies require the same manufacturing wait as CAR-T therapy?\u003c\/h3\u003e\n\u003cp\u003eNo. Bispecific antibodies are off-the-shelf therapies, meaning they are pre-made and ready to give, which allows rapid treatment initiation and broader patient access. CAR-T therapy requires personalized manufacturing and long processing times that can take weeks. This practical difference may matter if you need treatment quickly. Ask your care team whether a bispecific antibody is an option for your cancer type and setting.\u003c\/p\u003e\n\u003ch3\u003eWhat response rates were seen in relapsed or refractory follicular lymphoma?\u003c\/h3\u003e\n\u003cp\u003eIn relapsed or refractory follicular lymphoma, CD3-CD20 bispecific antibodies produced overall response rates of 80.00% to 95.06% and complete response rates of 60.00% to 82.72%. Median duration of response ranged from 18.00 to 22.80 months, and median progression-free survival was 17.90 months in one study. Response rates varied widely across lymphoma subtypes, so ask your care team how these group-level findings apply to you.\u003c\/p\u003e\n\u003ch3\u003eHow severe are the side effects, and do most patients stop treatment?\u003c\/h3\u003e\n\u003cp\u003eSerious adverse events occurred in 12.17% to 91.30% of patients, and grade 3 or higher adverse events in 27.42% to 95.65%. Despite this, treatment discontinuation generally remained below 20% across studies, and treatment-related mortality was uncommon. Two exceptions stood out: a phase I AML study reported 34.21% discontinuation, and a phase III DLBCL study reported 57.92%. Ask your care team how these ranges relate to your situation.\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient with relapsed or refractory B-cell precursor ALL, lymphoma, or multiple myeloma seek a second opinion about bispecific antibody treatment?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is worth considering when the cancer type or setting is unclear. Bispecific antibodies have established activity in B-cell precursor ALL, B-cell non-Hodgkin lymphoma, and multiple myeloma, but not in AML, Hodgkin lymphoma, or T-cell lymphoma, where they remain investigational with no approvals. Because response rates and side effects vary widely by target antigen, prior therapy, and disease, confirming which agent fits your CD19, CD20, BCMA, or GPRC5D profile matters. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Safety and efficacy of bispecific antibodies in hematologic neoplasms: a systematic review.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Lommuang K, Taychakhoonavudh S.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Immunology, Volume 17, Article 1815519\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticle type:\u003c\/strong\u003e Systematic Review\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication date:\u003c\/strong\u003e 11 August 2026\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3389\/fimmu.2026.1815519\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSystematic review registration:\u003c\/strong\u003e PROSPERO, identifier CRD42023467556 (https:\/\/www.crd.york.ac.uk\/PROSPERO\/)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKey words:\u003c\/strong\u003e bispecific antibodies, efficacy, hematologic neoplasms, safety, systematic review\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace personalized medical advice from your healthcare team.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47797516075164,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0599\/5449\/5644\/files\/ddn-medical-article-bispecific-antibodies-for-blood-cancers-what-a-major-review-of-36-studies-found-about-benefits-and-safety-hero.png?v=1791782462","url":"https:\/\/diagnosticdetectives.com\/fi\/products\/bispecific-antibodies-for-blood-cancers-what-a-major-review-of-36-studies-found-about-benefits-and-safety","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}